Considering the difference in CSC content observed between the different molecular breast cancer subtypes74, this suggests that BMP4-targeting therapies should be primarily developed and be more efficient for CSC enriched/driven tumors, such as basal-like or TNBC. The gene discussed is BMP4; the disease is breast cancer.